Back
Fosun Pharma Advances Lung Cancer Drug as NMPA Accepts Application
Back
Stock News
Themes
Fosun Pharma Advances Lung Cancer Drug as NMPA Accepts Application
Fosun Pharma Advances Lung Cancer Drug as NMPA Accepts Application
Edgen Stock
·
Jan 08 2026, 15:18
Share to
Share to
Copy link
FOSUN PHARMA
+0.05%
source:
[1] Fosun Pharma (600196.SH): Drug registration application for Furetinib Succinate Capsules accepted
Recommend
Agriculture ETFs Break Out on Fertilizer Supply Fears
Mar 06 2026, 16:17
Tango Therapeutics Stock Hits Record High on Erasca Cancer Trial Deal
Mar 06 2026, 16:02
Parker-Hannifin Stock Climbs 53% on Aerospace Demand
Mar 06 2026, 16:01
Features
AI Copilot for Stock & Crypto
Price Prediction
Fundraise Tracker
Themes
Crypto Comparison
Home Page
Resources
Tutorial
Gitbook
Team
Aura Insights
Market
US Market
HK Market
Crypto Market
Terms of Use
Privacy Policy
Sitemap
© 2026 Finture Development Limited. All rights reserved
Edgen Stock·Jan 08 2026, 15:18Edgen Stock·Jan 08 2026, 15:18
Edgen Stock·Jan 08 2026, 15:18